Retrospective cohort study to evaluate the efficacy and safety of T-DXd in HER2-positive unresectable advanced or recurrent gastric or gastroesophageal junction cancer: EN-DEAVOR study.

被引：0
|
作者：
Nakanishi, Koki
Kodera, Yasuhiro
Kawakami, Hisato
Makiyama, Akitaka
Konishi, Hirotaka
Morita, Satoshi
Narita, Yukiya
Sugimoto, Naotoshi
Minashi, Keiko
Imano, Motohiro
Inamoto, Rin
Kume, Hiroki
Yamaguchi, Keita
Hashimoto, Wataru
Muro, Kei
机构：
[1] Nagoya Univ, Grad Sch Med, Nagoya, Aichi, Japan
[2] Kindai Univ, Fac Med, Osaka, Japan
[3] Gifu Univ Hosp, Gifu, NA, Japan
[4] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Surg, Div Digest Surg, Kyoto, Japan
[5] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[6] Aichi Canc Ctr Hosp, Nagoya, Japan
[7] Osaka Int Canc Inst, Osaka, Japan
[8] Chiba Canc Ctr, Chiba, Japan
[9] Kindai Univ, Osaka, Japan
[10] Saitama Canc Ctr, Saitama, Japan
[11] Daiichi Sankyo Co Ltd, Tokyo, Japan
[12] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-492-199-2823; 613-135-244-3829-325; 298-11050; 613-135-2370-7650-2700; 130-273-572; 261-8931; 11890-11854-11942-11883; 5; 4; 3;
D O I：
10.1200/JCO.2024.42.3_suppl.274
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：274 / 274
页数：1
相关论文
共 50 条
  • [1] Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)RWD on T-DXd for gastric cancer in Japan
    Hisato Kawakami
    Koki Nakanishi
    Akitaka Makiyama
    Hirotaka Konishi
    Satoshi Morita
    Yukiya Narita
    Naotoshi Sugimoto
    Keiko Minashi
    Motohiro Imano
    Rin Inamoto
    Yasuhiro Kodera
    Hiroki Kume
    Keita Yamaguchi
    Wataru Hashimoto
    Kei Muro
    Gastric Cancer, 2025, 28 (1) : 51 - 61
  • [2] Correction: Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)
    Hisato Kawakami
    Koki Nakanishi
    Akitaka Makiyama
    Hirotaka Konishi
    Satoshi Morita
    Yukiya Narita
    Naotoshi Sugimoto
    Keiko Minashi
    Motohiro Imano
    Rin Inamoto
    Yasuhiro Kodera
    Hiroki Kume
    Keita Yamaguchi
    Wataru Hashimoto
    Kei Muro
    Gastric Cancer, 2025, 28 (1) : 62 - 62
  • [3] The efficacy and safety of trastuzumab for unresectable advanced HER2-positive gastric cancer
    Matsueda, Katsunori
    Toyokawa, Tatsuya
    Horii, Joichiro
    Fujita, Isao
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 95 - 95
  • [4] A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
    Fuchs, C.
    Shahidi, J.
    Mathew, L.
    Qin, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S150 - S150
  • [5] A phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Fuchs, Charles S.
    Shahidi, Javad
    Mathew, Lijoy
    Qin, Amy
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [6] Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
    Sawaki, Akira
    Ohashi, Yasuo
    Omuro, Yasushi
    Satoh, Taroh
    Hamamoto, Yasuo
    Boku, Narikazu
    Miyata, Yoshinori
    Takiuchi, Hiroya
    Yamaguchi, Kensei
    Sasaki, Yasutsuna
    Nishina, Tomohiro
    Satoh, Atsushi
    Baba, Eishi
    Tamura, Takao
    Abe, Takashi
    Hatake, Kiyohiko
    Ohtsu, Atsushi
    GASTRIC CANCER, 2012, 15 (03) : 313 - 322
  • [7] Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
    Akira Sawaki
    Yasuo Ohashi
    Yasushi Omuro
    Taroh Satoh
    Yasuo Hamamoto
    Narikazu Boku
    Yoshinori Miyata
    Hiroya Takiuchi
    Kensei Yamaguchi
    Yasutsuna Sasaki
    Tomohiro Nishina
    Atsushi Satoh
    Eishi Baba
    Takao Tamura
    Takashi Abe
    Kiyohiko Hatake
    Atsushi Ohtsu
    Gastric Cancer, 2012, 15 : 313 - 322
  • [8] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)
    Yamaguchi, K.
    Bang, Y.
    Iwasa, S.
    Sugimoto, N.
    Ryu, M.
    Sakai, D.
    Chung, H.
    Kawakami, H.
    Yabusaki, H.
    Lee, J.
    Saito, K.
    Kawaguchi, Y.
    Kamio, T.
    Kojima, A.
    Sugihara, M.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S235 - S235
  • [9] Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer
    Amane Jubashi
    Izuma Nakayama
    Shigehiro Koganemaru
    Naoya Sakamoto
    Shioto Oda
    Yuki Matsubara
    Yu Miyashita
    Seiya Sato
    Shinpei Ushiyama
    Akinori Kobayashi
    Ukyo Okazaki
    Dai Okemoto
    Kazumasa Yamamoto
    Saori Mishima
    Daisuke Kotani
    Akihito Kawazoe
    Tadayoshi Hashimoto
    Yoshiaki Nakamura
    Yasutoshi Kuboki
    Hideaki Bando
    Takashi Kojima
    Takayuki Yoshino
    Hisamitsu Miyaaki
    Kazuhiko Nakao
    Kohei Shitara
    Gastric Cancer, 2025, 28 (1) : 63 - 73
  • [10] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).
    Shitara, Kohei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-hee
    Sakai, Daisuke
    Chung, Hyun Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345